Stung by virus, Medimix finds its pull factor
Business Standard|March 24, 2020
The medicinal soap brand is seeing a sharp spurtin demand across the country ©
TE NARASIMHAN
Stung by virus, Medimix finds its pull factor

Over the past few weeks, Medimix, the low-key medicinal soap brand that was once the staple of budget hotels and rail travel has found itself thrust into the limelight. Born and sold as a cure for skin ailments, the brand that turned 50 last year has never seen such a massive crush at its shelves. So much so that the company is struggling to Keep up with demand.

Medimix is owned by two companies. Cholayil in the North run by the son of founder V P Sidhan, who is said to have mixed herbs and oils on his kitchen counter to make a medicinal mix and then named the soap thus, and AVA, in the South, owned by his son-in-law. Although the two are run as separate businesses, they share the brand name. And while Ava has seen a huge surge in demand, for Cholayil, there is a perceptible shift in the way the brand is being perceived.

A V Anoop, managing director, AVA Group says demand for the products, especially for hand wash (liquid soap) has increased by nearly 25 per cent. “The growth came as sweet surprise for the segment, which was de- growing,” he said.

Diese Geschichte stammt aus der March 24, 2020-Ausgabe von Business Standard.

Starten Sie Ihre 7-tägige kostenlose Testversion von Magzter GOLD, um auf Tausende kuratierte Premium-Storys sowie über 8.000 Zeitschriften und Zeitungen zuzugreifen.

Diese Geschichte stammt aus der March 24, 2020-Ausgabe von Business Standard.

Starten Sie Ihre 7-tägige kostenlose Testversion von Magzter GOLD, um auf Tausende kuratierte Premium-Storys sowie über 8.000 Zeitschriften und Zeitungen zuzugreifen.

WEITERE ARTIKEL AUS BUSINESS STANDARDAlle anzeigen
Spices under scanner: Govt panel gives report
Business Standard

Spices under scanner: Govt panel gives report

The govt is launching an initiative to ensure India's exports meet importing countries' tolerance limits

time-read
1 min  |
May 01, 2024
AstraZeneca vaccine: The controversy continues
Business Standard

AstraZeneca vaccine: The controversy continues

The controversial AstraZeneca Covid-19 vaccine, which was banned by several countries across the globe after multiple cases of blood clots were reported in patients who were administered the jab, is back in the spotlight.

time-read
2 Minuten  |
May 01, 2024
BRIDGING THE GAP
Business Standard

BRIDGING THE GAP

Why the surge of hybrid cars is being seen as an essential transition phase to electric

time-read
4 Minuten  |
May 01, 2024
M&M, TaMo, Maruti: Auto stocks to stay in fast lane
Business Standard

M&M, TaMo, Maruti: Auto stocks to stay in fast lane

The uptrend in auto sector to continue in the near term, believe analysts

time-read
2 Minuten  |
May 01, 2024
Business Standard

Parcel fraud: Suspect a scam call? Disengage immediately

Verify the call's authenticity; resist pressure to pay up or share sensitive information

time-read
3 Minuten  |
May 01, 2024
High growth and margin expectations to drive Trent
Business Standard

High growth and margin expectations to drive Trent

THE COMPASS DEVANGSHU DATTA Zudio could lead to further upgrades.

time-read
2 Minuten  |
May 01, 2024
Business Standard

FOPs ready to roll out bit-sized Reits

Many real estate ownership platforms to file with markets regulator under recently notified norms

time-read
3 Minuten  |
May 01, 2024
Why are RBI, other banks on a gold-buying spree?
Business Standard

Why are RBI, other banks on a gold-buying spree?

The Reserve Bank of India (RBI), like most other global central banks, is on a gold buying spree.

time-read
2 Minuten  |
May 01, 2024
Business Standard

Mkts slide after fresh record highs

The National Stock Exchange (NSE) benchmark Nifty rose for the second day underpinned by gains in index heavyweights to hit fresh record highs on an intraday basis but came off from the day's highs to end the trading session with losses.

time-read
1 min  |
May 01, 2024
Business Standard

ChrysCapital closes its $700 mn continuation fund

ChrysCapital on Tuesday closed its $700 million continuation fund, which will allow the private equity firm to hang onto its stake in the National Stock Exchange (NSE), which it first bought in 2016.

time-read
1 min  |
May 01, 2024